Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. (Q36672726)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

11 December 2020

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

26 February 2020

main subject

multiple sclerosis

0 references

5 references

25 April 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

11 December 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Alasdair J Coles

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

language of work or name

English

0 references

publication date

6 March 2013

7 references

25 April 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

11 December 2020

Drug Design, Development and Therapy

7 references

25 April 2019

30 June 2019

27 September 2019

27 November 2019

13 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

11 December 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

131-138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 3.0 Unported

26 February 2020

copyright license

start time

1 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

The evidence for a role of B cells in multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3593763

[Effect of Campath-1H induction on immunosuppression in small intestine transplantation]

20 September 2018

1 reference

12 December 2020

A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis

1 reference

12 December 2020

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies

1 reference

12 December 2020

Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy

1 reference

12 December 2020

Identifiers

DOI

10.2147/DDDT.S32687

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494602%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference